JP2014527061A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527061A5
JP2014527061A5 JP2014527322A JP2014527322A JP2014527061A5 JP 2014527061 A5 JP2014527061 A5 JP 2014527061A5 JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527061 A5 JP2014527061 A5 JP 2014527061A5
Authority
JP
Japan
Prior art keywords
methyl
imidazol
carbonyl
hcv
biphenylyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052216 external-priority patent/WO2013028953A1/en
Publication of JP2014527061A publication Critical patent/JP2014527061A/ja
Publication of JP2014527061A5 publication Critical patent/JP2014527061A5/ja
Pending legal-status Critical Current

Links

JP2014527322A 2011-08-24 2012-08-24 C型肝炎の組合せ治療 Pending JP2014527061A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US61/526,798 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US61/529,358 2011-08-31
US201261617813P 2012-03-30 2012-03-30
US61/617,813 2012-03-30
PCT/US2012/052216 WO2013028953A1 (en) 2011-08-24 2012-08-24 Combination treatments for hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083252A Division JP2017165746A (ja) 2011-08-24 2017-04-20 C型肝炎の組合せ治療

Publications (2)

Publication Number Publication Date
JP2014527061A JP2014527061A (ja) 2014-10-09
JP2014527061A5 true JP2014527061A5 (https=) 2015-10-08

Family

ID=47746891

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014527322A Pending JP2014527061A (ja) 2011-08-24 2012-08-24 C型肝炎の組合せ治療
JP2017083252A Pending JP2017165746A (ja) 2011-08-24 2017-04-20 C型肝炎の組合せ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017083252A Pending JP2017165746A (ja) 2011-08-24 2017-04-20 C型肝炎の組合せ治療

Country Status (18)

Country Link
US (1) US20140234253A1 (https=)
EP (1) EP2747569A4 (https=)
JP (2) JP2014527061A (https=)
KR (1) KR20140065427A (https=)
CN (1) CN103917095A (https=)
AU (1) AU2012298750A1 (https=)
BR (1) BR112014004182A2 (https=)
CA (1) CA2845321A1 (https=)
CL (1) CL2014000428A1 (https=)
CO (1) CO6890100A2 (https=)
CR (1) CR20140086A (https=)
EA (1) EA201490254A1 (https=)
HK (1) HK1198869A1 (https=)
IL (1) IL230844A0 (https=)
MX (1) MX2014002171A (https=)
PH (1) PH12014500386A1 (https=)
SG (1) SG2014010490A (https=)
WO (1) WO2013028953A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
MX2014001833A (es) * 2011-08-17 2014-02-27 Glaxosmithkline Llc Metodos terapeuticos.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9447132B2 (en) 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015005901A1 (en) * 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
US9512108B2 (en) * 2013-12-31 2016-12-06 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof
CN106279122A (zh) * 2014-01-21 2017-01-04 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业(浙江)有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110229438A1 (en) * 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
JP2012514605A (ja) * 2009-01-07 2012-06-28 サイネクシス,インコーポレーテッド Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体
HUE030465T2 (hu) * 2009-05-13 2017-05-29 Antivirális vegyületek
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012006877A (es) * 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs

Similar Documents

Publication Publication Date Title
JP2014527061A5 (https=)
AU2014239563B2 (en) Combination of two antivirals for treating hepatitis C
US8415374B2 (en) Combinations of hepatitis C virus inhibitors
US20130072528A1 (en) Methods for Treating HCV
ES2654109T3 (es) Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC
CA2942823C (en) Methods for treating hcv
JP2017165746A (ja) C型肝炎の組合せ治療
EP2773342A1 (en) Compositions useful for the treatment of viral diseases
US20130172240A1 (en) Methods for treating hcv
JP2016523924A (ja) Hcvの治療方法
AU2015240753B2 (en) Methods for treating HCV
US20140024613A1 (en) Methods for Treating HCV
US20170360783A1 (en) Methods for Treating HCV
US20200330460A1 (en) Methods for Treating HCV
EP3437643A1 (en) Methods for treating hcv
EP3360555A1 (en) Methods for treating hcv
HK40004326A (en) Methods for treating hcv
WO2016134058A1 (en) Combinations useful to treat hepatitis c virus